论文部分内容阅读
目的观察黛力新(氟哌噻吨美利曲辛)联合伊托必利治疗便秘型肠易激综合征的临床疗效。方法便秘型肠易激综合征患者65例随机分为两组:对照组33例,口服伊托必利50mg,每日3次;治疗组32例,在对照组基础上加用口服黛力新10.5mg,每日早晨、中午各1次。疗程均为1个月。比较两组的临床疗效、焦虑及抑郁症状的改善及不良反应发生情况。结果治疗后,治疗组总有效率高于对照组(93.75%vs.69.70%)(P<0.05),汉密顿焦虑量表和汉密顿抑郁量表评分均低于对照组[(7.86±3.77)分vs.(17.87±4.68)分和(12.01±4.31)分vs.(24.16±6.74)分](P<0.05)。两组均未见明显不良反应。结论与单用伊托必利比较,黛力新联合伊托必利更能改善便秘型肠易激综合征患者的焦虑及抑郁症状。
Objective To observe the clinical efficacy of dextromethorphan (flupenthixol and melitracen) combined with itopride in the treatment of constipation-type irritable bowel syndrome. Methods 65 patients with constipation-type irritable bowel syndrome were randomly divided into two groups: control group of 33 patients, oral itopride 50mg, 3 times a day; treatment group of 32 patients on the basis of the control group plus oral Deanxit 10.5mg, daily morning, noon each time. Treatment are 1 month. The clinical efficacy, anxiety and depression symptoms and adverse reactions in the two groups were compared. Results After treatment, the total effective rate in the treatment group was significantly higher than that in the control group (93.75% vs.69.70%, P <0.05). The scores of the Hamilton Anxiety Scale and the Hamilton Depression Scale were lower than those in the control group [(7.86 ± 3.77) points vs (17.87 ± 4.68) points and (12.01 ± 4.31) points vs. (24.16 ± 6.74) points respectively (P <0.05). No obvious adverse reactions were found in both groups. Conclusion Compared with etopride alone, combination of dextromethorphan and itopride can ameliorate the symptoms of anxiety and depression in patients with constipation-predominant irritable bowel syndrome.